Market Cap
CHF89.7m
Last Updated
2021/01/16 18:12 UTC
Data Sources
Company Financials +
Executive Summary
Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with high growth potential.
Share Price & News
How has Polyphor's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: POLN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: POLN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
Market Performance
7 Day Return
-1.8%
POLN
3.6%
CH Biotechs
0.4%
CH Market
1 Year Return
7.4%
POLN
1.3%
CH Biotechs
-0.4%
CH Market
Return vs Industry: POLN exceeded the Swiss Biotechs industry which returned 1.3% over the past year.
Return vs Market: POLN exceeded the Swiss Market which returned -0.4% over the past year.
Shareholder returns
| POLN | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.8% | 3.6% | 0.4% |
| 30 Day | -1.2% | 1.5% | 2.8% |
| 90 Day | -10.3% | 2.0% | 5.8% |
| 1 Year | 7.4%7.4% | 2.6%1.3% | 3.1%-0.4% |
| 3 Year | n/a | 4.3%1.9% | 19.8%4.7% |
| 5 Year | n/a | 71.8%66.0% | 51.9%26.8% |
Long-Term Price Volatility Vs. Market
How volatile is Polyphor's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Polyphor AG's (VTX:POLN) Shift From Loss To Profit1 year ago | Simply Wall St
Introducing Polyphor (VTX:POLN), The Stock That Slid 61% In The Last Year1 year ago | Simply Wall St
Can We See Significant Insider Ownership On The Polyphor AG (VTX:POLN) Share Register?Valuation
Is Polyphor undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: POLN (CHF8) is trading below our estimate of fair value (CHF252.13)
Significantly Below Fair Value: POLN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: POLN is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: POLN is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate POLN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: POLN's PB Ratio (3x) is in line with the CH Biotechs industry average.
Next Steps
Future Growth
How is Polyphor forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
60.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: POLN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.3%).
Earnings vs Market: POLN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: POLN's is expected to become profitable in the next 3 years.
Revenue vs Market: POLN's revenue (43.3% per year) is forecast to grow faster than the Swiss market (4.6% per year).
High Growth Revenue: POLN's revenue (43.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: POLN is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Polyphor performed over the past 5 years?
-19.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: POLN is currently unprofitable.
Growing Profit Margin: POLN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: POLN is unprofitable, and losses have increased over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare POLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: POLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).
Return on Equity
High ROE: POLN has a negative Return on Equity (-218.38%), as it is currently unprofitable.
Next Steps
Financial Health
How is Polyphor's financial position?
Financial Position Analysis
Short Term Liabilities: POLN's short term assets (CHF47.2M) exceed its short term liabilities (CHF13.4M).
Long Term Liabilities: POLN's short term assets (CHF47.2M) exceed its long term liabilities (CHF14.7M).
Debt to Equity History and Analysis
Debt Level: POLN's debt to equity ratio (7.5%) is considered satisfactory.
Reducing Debt: POLN's debt to equity ratio has reduced from 8.9% to 7.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: POLN has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: POLN is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.
Next Steps
Dividend
What is Polyphor current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate POLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate POLN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if POLN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if POLN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of POLN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.6yrs
Average management tenure
CEO
Gokhan Batur (38 yo)
1
Tenure
Mr. Gokhan Batur has been the Chief Executive Officer at Polyphor AG since January 23, 2020 and had been its Chief Commercial Officer since June 3, 2019 until January 23, 2020. Mr. Batur joined Polyphor in...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1yr | no data | no data | |
| Co-Founder & Chief Scientific Officer | 25yrs | no data | 1.74% CHF 1.6m | |
| Chief Financial Officer | 1.25yrs | no data | no data | |
| Head of Human Resources | no data | no data | 0.012% CHF 11.2k | |
| Chief Medical & Development Officer | 2yrs | no data | no data |
1.6yrs
Average Tenure
45yo
Average Age
Experienced Management: POLN's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 1.17yrs | no data | 0.045% CHF 40.0k | |
| Director | 4.58yrs | no data | 0.16% CHF 142.0k | |
| Director | 7.58yrs | no data | 0.047% CHF 41.9k | |
| Vice Chairman | 1.17yrs | no data | no data |
2.9yrs
Average Tenure
59yo
Average Age
Experienced Board: POLN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Polyphor AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Polyphor AG
- Ticker: POLN
- Exchange: SWX
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF89.667m
- Shares outstanding: 11.21m
- Website: https://www.polyphor.com
Number of Employees
Location
- Polyphor AG
- Hegenheimermattweg 125
- Allschwil
- Basel-Landschaft
- 4123
- Switzerland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| POLN | SWX (SIX Swiss Exchange) | Yes | Common Shares | CH | CHF | May 2018 |
| 29Y | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | May 2018 |
Biography
Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. Its lead drug candidates include Balixafortide (POL6326), an antagonist of the chemokine receptor...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/16 18:12 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.